Verition Fund Management
ABBV icon

Verition Fund Management’s AbbVie ABBV Stock Holding History

Verition Fund Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
14,600
+1,800
+14% +$387K 0.02% 806
2026
Q1 		$2.78M Sell
12,800
-15,700
-55% -$3.48M 0.02% 853
2025
Q4 		$6.51M Sell
28,500
-3,300
-10% -$752K 0.03% 698
2025
Q3 		$7.36M Sell
31,800
-8,000
-20% -$1.63M 0.03% 765
2025
Q2 		$7.39M Buy
39,800
+18,000
+83% +$3.35M 0.03% 731
2025
Q1 		$4.57M Sell
21,800
-10,900
-33% -$2.12M 0.02% 904
2024
Q4 		$5.81M Sell
32,700
-200
-0.6% -$36.8K 0.02% 798
2024
Q3 		$6.5M Sell
32,900
-9,200
-22% -$1.72M 0.03% 668
2024
Q2 		$7.22M Buy
42,100
+22,800
+118% +$3.78M 0.04% 514
2024
Q1 		$3.51M Buy
19,300
+2,800
+17% +$483K 0.02% 897
2023
Q4 		$2.56M Buy
16,500
+10,000
+154% +$1.46M 0.02% 721
2023
Q3 		$969K Buy
6,500
+4,400
+210% +$646K 0.01% 1100
2023
Q2 		$283K Buy
+2,100
New +$308K ﹤0.01% 1600
2023
Q1 		– Sell
-30,300
Closed -$4.9M – 2116
2022
Q4 		$4.9M Sell
30,300
-9,900
-25% -$1.52M 0.08% 314
2022
Q3 		$5.39M Buy
+40,200
New +$5.77M 0.06% 382
2022
Q2 		– Sell
-46,500
Closed -$7.54M – 2274
2022
Q1 		$7.54M Buy
46,500
+7,800
+20% +$1.13M 0.09% 228
2021
Q4 		$5.24M Buy
+38,700
New +$4.57M 0.04% 341
2021
Q1 		– Sell
-259,200
Closed -$27.8M – 1511
2020
Q4 		$27.8M Sell
259,200
-11,200
-4% -$1.08M 0.24% 67
2020
Q3 		$23.7M Sell
270,400
-152,900
-36% -$14.4M 0.47% 33
2020
Q2 		$41.6M Sell
423,300
-131,100
-24% -$11.5M 1.37% 12
2020
Q1 		$42.2M Buy
554,400
+45,000
+9% +$3.83M 1.67% 11
2019
Q4 		$44.5M Sell
509,400
-122,100
-19% -$10.1M 0.81% 24
2019
Q3 		$47.1M Buy
631,500
+78,300
+14% +$5.37M 1.3% 13
2019
Q2 		$40.2M Buy
+553,200
New +$43.5M 1.13% 16

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Verition Fund Management's ABBV Position: Q2 2026 in Review

Verition Fund Management increased its AbbVie (ABBV) stake by 314% in Q2 2026, buying an estimated $2.4M and bringing the position to 14,719 shares worth $3.7M. The position accounts for 0.02% of the portfolio, ranked #797.

Verition Fund Management first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $16.4M in Q1 2020. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Verition Fund Management held 14,719 shares of AbbVie worth $3.7M as of Q2 2026.
  • Verition Fund Management bought 11,166 AbbVie shares in Q2 2026, an estimated $2.4M.
  • AbbVie made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #797 holding.
  • Verition Fund Management first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
  • Verition Fund Management's AbbVie position peaked at $16.4M in Q1 2020.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.